KoDiscovery

KO Discovery is a private biotechnology company based in San Diego, California, focused on the discovery and development of novel small molecule therapeutics for oncology and inflammatory diseases. The company specializes in targeting the ubiquitin-proteasome system (UPS), specifically deubiquitinating enzymes (DUBs) such as USP7, USP14, and UCHL5. Its lead research programs are centered on USP7 inhibitors, which have demonstrated potential in treating multiple myeloma and various solid tumors by promoting the degradation of oncogenic proteins and stabilizing tumor suppressors. By leveraging a proprietary drug discovery platform, KO Discovery aims to identify potent and selective inhibitors for these challenging targets. The company is currently in the pre-clinical stage of development and is led by industry veterans with deep expertise in medicinal chemistry and UPS biology.